Key strengths include strong product-level economics with high gross margins, a substantial and growing biosimilar pipeline, and an integrated development and manufacturing platform that provides control over quality and costs. The company benefits from global partnerships that extend its commercial reach without massive sales investments, and it maintains adequate short-term liquidity despite high investment needs. Its focused expertise in biosimilars and demonstrated ability to secure approvals in major markets add to its strategic positioning.

The main risks are financial and execution-related. A very high debt load and negative equity position create meaningful solvency concerns over the medium term, especially given negative operating and free cash flow. The business remains dependent on external financing, which may become more difficult or expensive if market conditions turn or if operational performance disappoints. Competitive intensity, pricing pressure in biosimilars, and regulatory or manufacturing setbacks—particularly at its core facility—could further strain margins and cash flows.

Looking ahead, Alvotech’s outlook hinges on two parallel tracks: commercial and financial. Commercially, the company is well positioned to benefit from the global growth of biosimilars if it can continue winning approvals, expanding its product lineup, and deepening penetration through its partners. Financially, it will need to improve cash generation, manage costs, and address its heavy leverage for the story to become more durable. The opportunity is significant, but so are the execution and balance sheet risks, making future results and trend developments especially important to monitor.